Pilot Feasibility Study of Neurofeedback for Attention Deficit Hyperactivity Disorder (ADHD)
Pilot Explorations of Neurofeedback Issues in ADHD
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Nisonger Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6-12 inclusive.
- Boys and girls.
- Primary diagnosis of ADHD, inattentive or combined type.
- Not currently taking medication for ADHD.
- Primary caretaker who can provide frequent parent ratings.
- Item mean ≥1.5 on a 0-3 metric on parent/teacher ratings of DSM-IV inattentive symptoms or on parent/teacher ratings of all 18 ADHD symptoms (while off medication).
- IQ 80 or above and mental age of 6 years or more.
- Willingness and ability to come for 40 treatment sessions and to cooperate with assessments.
- Informed consent and assent
Exclusion Criteria:
- Comorbid disorder requiring psychoactive medication including psychosis, bipolar disorder, severe major depression, and severe anxiety disorders. Patients with mild depression or anxiety not requiring pharmacotherapy will be included and the comorbid symptoms will be tracked.Pervasive developmental disorder is exclusionary by DSM-IV definition of ADHD.
- Medical disorder requiring systemic chronic medication that has confounding psychoactive effects. Asthma inhalants will be allowed, but not chronic systemic corticoids.
- Mental Retardation.
- Anything that would interfere with assessments or study treatment or contraindicate study treatment.
- Plans to move requiring school change during the next 4 months.
- Antipsychotic agent in the 6 months prior to baseline assessment, fluoxetine or atomoxetine in the 4 weeks prior to baseline, stimulant in the week prior to baseline, or other psychiatric medication in the two weeks prior to baseline.
- Previous neurofeedback training of more than 5 treatments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active neurofeedback
In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency.
Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface.
the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio.
If theta power exceeds a threshold, the rumble function of the controller comes on as a warning.
The feedback is transparent to the patient, who just plays the videogame.
|
A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
Other Names:
|
|
Sham Comparator: Sham Neurofeedback
The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices.
The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
|
Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Double-blind, Sham-controlled Design #1. Recruitment Number
Time Frame: 2 years
|
The feasibility of the double-blind, sham-controlled design was examined in 3 ways, this first way was via the number of participants recruited.
|
2 years
|
|
Feasibility of Double-blind, Sham-controlled Design #2. Retention
Time Frame: 40th treatment sessions ~ 13-20 weeks
|
The feasibility of the double-blind, sham-controlled design was examined in 3 ways.
The second way was via the percentage of participants retained the end of treatment (40th session).
|
40th treatment sessions ~ 13-20 weeks
|
|
Feasibility of Double-blind, Sham-controlled Design #3. Validity of Blind
Time Frame: Post-treatment at session 40
|
The feasibility of the double-blind, sham-controlled design was examined in 3 ways.
The 3rd way was the percentage of child and parent post-hoc guess regarding treatment assignment.
|
Post-treatment at session 40
|
|
Frequency Advisability Outcome (2X vs. 3X/wk) #1 Parent & Child Satisfaction
Time Frame: 24 treatments ~ 8-12 weeks
|
Parent & child satisfaction of treatment frequency (x2 vs x3 treatments per week) was measured on a likert scale with anchors 0 (indicating low satisfaction) and 7 (indicating high satisfaction).
|
24 treatments ~ 8-12 weeks
|
|
Frequency Advisability Outcome (2X vs. 3X/wk) #2. Treatment Frequency Choice
Time Frame: 24 treatments ~ 8-12 weeks
|
Treatment frequency preference when given choice to change or not to change treatment frequency from 2 to 3X/wk or 3 to 2X/wk at treatment # 24.
|
24 treatments ~ 8-12 weeks
|
|
Necessary Duration of Treatment
Time Frame: 40 treatment sessions ~ 13-20 weeks
|
The necessary duration of treatments was examined via identifying the number of treatments at which improvement stabilized, as shown visually on graphs of parent-rated ADHD symptoms from the SNAP-IV (0-3 scale, lower score is better) for those participants in the Active Neurofeedback who completed 40 treatment sessions.The Sham group is not included in this outcome.
|
40 treatment sessions ~ 13-20 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: L. Eugene Arnold, M.Ed., M.D., Ohio State University
Publications and helpful links
General Publications
- Lofthouse N, Arnold LE, Hersch S, Hurt E, DeBeus R. A review of neurofeedback treatment for pediatric ADHD. J Atten Disord. 2012 Jul;16(5):351-72. doi: 10.1177/1087054711427530. Epub 2011 Nov 16.
- Arnold LE, Lofthouse N, Hersch S, Pan X, Hurt E, Bates B, Kassouf K, Moone S, Grantier C. EEG neurofeedback for ADHD: double-blind sham-controlled randomized pilot feasibility trial. J Atten Disord. 2013 Jul;17(5):410-9. doi: 10.1177/1087054712446173. Epub 2012 May 22.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2008H0019-A
- 1R34MH080775-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.